You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma

 

Online download statistics by month:

Online download statistics by month: September 2022 to July 2025

AbstractFullPdf
Sep 2022489499127
Oct 202216717348
Nov 2022868826
Dec 2022686814
Jan 2023494911
Feb 2023565723
Mar 202325257
Apr 202337385
May 2023313214
Jun 202332326
Jul 2023272814
Aug 202354549
Sep 202328287
Oct 2023525216
Nov 202331315
Dec 202330306
Jan 2024303110
Feb 2024323215
Mar 2024323233
Apr 2024383815
May 2024313215
Jun 2024454413
Jul 2024555617
Aug 2024252211
Sep 2024292913
Oct 2024252513
Nov 202423248
Dec 2024323312
Jan 2025262615
Feb 202512121
Mar 2025161616
Apr 2025363710
May 2025202016
Jun 2025141511
Jul 2025110
Total17841809582